Fosun Pharma raises $512 million, while Dynasty Reit cancels IPO

The market remains challenging for new listings and both deals attract modest demand from international investors, with Fosun forced to reallocate shares to retail investors to make up for the lack of institutional interest.

Fosun Pharma raises $512 million, while Dynasty Reit cancels IPO

Shanghai Fosun Pharmaceutical has raised HK$3.97 billion $512 million after pricing its Hong Kong initial public offering at the bottom of the indicated range.

The company, which is already listed in Shanghai, will be the largest new listing in Hong Kong in three months, but it is still unlikely to give issuers in the pipeline the reassurance they are looking for with regard to investor appetite for IPOs.

A key...

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition

CONFERENCES